Enlisting the Immune System to Treat Skin Cancer
The FDA approved the use of an immune checkpoint inhibitor to treat certain patients with cutaneous squamous cell carcinoma. ...
Progress Against Cancer
The FDA approved the use of an immune checkpoint inhibitor to treat certain patients with cutaneous squamous cell carcinoma. ...
Editor’s Note: On April 30, 2026, the FDA withdrew the accelerated approval of selinexor for this indication. The FDA...
The FDA approved the use of a companion diagnostic to identify patients with tumors that have large numbers of...
The FDA approved an analog of a marine compound to treat certain patients with small cell lung cancer. The...
The FDA approved the use of an immune checkpoint inhibitor to treat certain patients with a common form of...
The FDA approved a combination of an immunotherapy and a therapeutic that can stop tumors from growing blood vessels...
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients who have advanced gastrointestinal stromal tumors. The...
The FDA has expanded the use of a molecularly targeted therapeutic to include the treatment of certain patients with...
The FDA has approved a combination of nivolumab and ipilimumab to treat certain patients with metastatic lung cancer. The...